Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with the Canadian Glycomics Network (GlycoNet) aimed at translating glycomics research into treatments for genetic diseases. The partnership intends to foster research programs and clinical investigations, leveraging glycomics insights for therapeutic advancements. BridgeBio has previously partnered with various academic institutions, enhancing its research capabilities. This collaboration is expected to streamline the development of treatments for genetic disorders, addressing unmet medical needs.
BridgeBio Pharma (NASDAQ: BBIO) has partnered with Brown University to enhance research in genetically driven neurological disorders. The collaboration aims to advance treatment methods for complex brain diseases, leveraging Brown's neurology expertise. Under this partnership, promising discoveries will be evaluated, with opportunities for Brown scientists to take leadership roles in developing therapeutic programs. This collaboration is part of BridgeBio's strategy to translate genetic research into viable medicines, complementing its existing 20 partnerships with leading academic institutions.
BridgeBio Pharma granted restricted stock units totaling 32,691 shares to 19 new employees, as part of its 2019 Inducement Equity Plan. The awards were announced on April 5, 2021, following Nasdaq Listing Rule 5635(c)(4), which requires such grants as inducements for employees entering the company. BridgeBio focuses on developing transformative medications for genetic diseases and cancers, with a pipeline of over 30 development programs from early science to advanced clinical trials.
BridgeBio and Helsinn have entered a global collaboration to co-commercialize infigratinib for oncology, sharing profits equally. Helsinn will exclusively develop and commercialize infigratinib outside the U.S., excluding China and nearby regions. BridgeBio stands to gain over $2 billion in milestone payments. The FDA has granted Priority Review for infigratinib for cholangiocarcinoma, highlighting its potential in treating FGFR-driven cancers. This partnership aims to accelerate the launch and broaden research into infigratinib's applications.
BridgeBio Pharma (Nasdaq: BBIO) announced promising early results from a Phase 2b study of encaleret for treating Autosomal Dominant Hypocalcemia Type 1 (ADH1). Out of six participants, 100% showed normalization of blood and urine calcium levels within five days. Encaleret was reported to be well-tolerated with no serious adverse events, suggesting significant efficacy potential. The company plans to discuss regulatory pathways in 2021 to potentially become the first approved therapy for ADH1. A webcast to discuss these results is scheduled for March 22, 2021.
On March 1, 2021, BridgeBio Pharma (Nasdaq: BBIO) granted 17 new employees a total of 30,510 restricted stock units under its 2019 Inducement Equity Plan. This award serves as an incentive for new employees in alignment with Nasdaq Listing Rule 5635(c)(4). The Plan, established by BridgeBio's board in November 2019, is aimed at promoting employee engagement and retention. Founded in 2015, BridgeBio focuses on developing medicines for genetic diseases and has over 30 programs in its pipeline.
BridgeBio Pharma announced FDA approval for NULIBRY (fosdenopterin), the first therapy for molybdenum cofactor deficiency (MoCD) Type A. This ultra-rare genetic disorder affects under 150 patients globally, with a median survival age of four years. NULIBRY showed an 82% reduction in mortality risk compared to untreated patients during clinical trials, offering new hope for affected families. The approval includes Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease Designation, along with a Rare Pediatric Disease Priority Review Voucher.
BridgeBio Pharma recently completed its acquisition of Eidos Therapeutics, enhancing its ability to develop acoramidis, a promising treatment for amyloidosis cardiomyopathy. The FDA accepted its NDA for infigratinib to treat cholangiocarcinoma under Priority Review, expediting the approval process. The company initiated two new clinical trials and progressed 17 ongoing studies. As of December 31, 2020, BridgeBio held $607.1 million in cash and marketable securities, following a significant financing round that raised nearly $750 million, positioning it for upcoming product launches.
BridgeBio Pharma (Nasdaq: BBIO) is set to host a webcast on March 22 at 8:00 a.m. ET, to discuss early results from a Phase 2 proof-of-concept study of encaleret for treating Autosomal Dominant Hypocalcemia Type 1 (ADH1). The data will also be presented at the ENDO 2021 conference. If successful, encaleret could be the first approved therapy for ADH1, affecting approximately 12,000 people in the U.S. The company will also present data on infigratinib for children with achondroplasia and a gene therapy candidate for Congenital Adrenal Hyperplasia (CAH).
BridgeBio Pharma (Nasdaq: BBIO) has announced the dosing of the first patient in a Phase 2 trial for BBP-418, an oral treatment for LGMD2i, a serious genetic muscle disorder. This investigational therapy received Orphan Drug Designation from the FDA and EMA due to its potential to address a critical unmet medical need. The trial aims to enroll up to 16 patients, focusing on safety and key efficacy indicators such as muscle glycosylation and functional measures. The progress in this trial represents a significant step towards developing effective therapies for LGMD2i patients.